- Home
- FIEE vs OTLK Comparison
FIEE vs OTLK Comparison
Compare FIEE & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FIEE | OTLK |
|---|---|---|
| Founded | 1977 | 2010 |
| Country | Hong Kong | United States |
| Employees | 43 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 37.5M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | FIEE | OTLK |
|---|---|---|
| Price | $5.19 | $0.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 6.6K | ★ 23.3M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.16 |
| 52 Week High | $7.95 | $3.39 |
Technical Indicators
Market Signals| Indicator | FIEE | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 40.08 | 80.66 |
| Support Level | $2.40 | $0.79 |
| Resistance Level | $7.28 | $1.18 |
| Average True Range (ATR) | 0.36 | 0.10 |
| MACD | -0.07 | 0.06 |
| Stochastic Oscillator | 37.40 | 80.57 |
Price Performance
Historical ComparisonAbout FIEE FiEE Inc
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.